These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3651528)

  • 1. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
    Hollander E; Davidson M; Mohs RC; Horvath TB; Davis BM; Zemishlany Z; Davis KL
    Biol Psychiatry; 1987 Sep; 22(9):1067-78. PubMed ID: 3651528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
    Talwalker S
    J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism.
    Noring U; Povlsen UJ; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1984; 84(4):569-71. PubMed ID: 6152058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
    Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
    Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clipp EC; Moore MJ
    Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
    Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
    Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
    Katada E; Sato K; Sawaki A; Dohi Y; Ueda R; Ojika K
    J Geriatr Psychiatry Neurol; 2003 Mar; 16(1):39-43. PubMed ID: 12641372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic drugs as diagnostic and therapeutic tools in affective disorders.
    Berger M; Riemann D; Krieg C
    Acta Psychiatr Scand Suppl; 1991; 366():52-60. PubMed ID: 1897376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
    Weyer G; Babej-Dölle RM; Hadler D; Hofmann S; Herrmann WM
    Neuropsychobiology; 1997; 36(2):73-82. PubMed ID: 9267856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic approaches to the treatment of Alzheimer's disease.
    Hollander E; Mohs RC; Davis KL
    Br Med Bull; 1986 Jan; 42(1):97-100. PubMed ID: 3006861
    [No Abstract]   [Full Text] [Related]  

  • 18. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.
    Davidson M; Stern RG
    Psychiatr Clin North Am; 1991 Jun; 14(2):461-82. PubMed ID: 2062728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.